PET-DOPA Metabolic Detection and Characterization of Untreated Brain Metastases of Bronchial, Breast and Melanoma Cancer

Phase 1

Recruiting

• Conditions: patients with newly discovered brain metastases (non-small cell lung cancer, breast cancer or melanoma) measuring more than 5 mm and explored on MRI; MedDRA version: 27.0Level: PTClassification code: 10059515Term: Non-small cell lung cancer metastatic Class: 100000004864; MedDRA version: 27.0Level: LLTClassification code: 10027475Term: Metastatic breast cancer Class: 10029104; MedDRA version: 27.0Level: PTClassification code: 10027480Term: Metastatic malignant melanoma Class: 100000004864; Therapeutic area: Diseases [C] - Neoplasms [C04]

• Registration Number: CTIS2024-515850-26-00
• Lead Sponsor: Institut De Cancerologie De L Ouest

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2024-06-27
• Last Update Posted: 22 July 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 52

Inclusion Criteria

Histologically proven primary cancer (non-small cell lung, breast or melanoma), 2) Presence of brain metastasis(s) visualized on MRI, with at least 1 measuring more than 5 mm, 3) Age = 18 years

Exclusion Criteria

1) History of cerebral irradiation, 2) Previous brain surgery for brain metastasis or glial tumor, 3) Systemic therapy (chemotherapy, targeted therapy, immunotherapy) modified in the 6 weeks preceding the PET-DOPA scan,, 4) New anti-tumor treatment (excluding corticosteroids) started between the discovery of CD and the performance of the PET-DOPA scan, 5) Other concomitant cancer, or history of cancer in the 5 years preceding the patient's inclusion in the protocol other than basal or squamous cell carcinoma, 6) Pregnant, likely to be pregnant or breastfeeding

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified